A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

BACKGROUND: Neo-adjuvant chemoradiotherapy followed by surgery is the standard treatment with curative intent for oesophageal cancer patients, with 5-year overall survival rates up to 50 %. However, patients’ quality of life is severely compromised by oesophagectomy, and eventually many patients die...

Descripción completa

Detalles Bibliográficos
Autores principales: Larue, Ruben T. H. M., Van De Voorde, Lien, Berbée, Maaike, van Elmpt, Wouter J. C., Dubois, Ludwig J., Panth, Kranthi M., Peeters, Sarah G. J. A., Claessens, Ann, Schreurs, Wendy M. J., Nap, Marius, Warmerdam, Fabiënne A. R. M., Erdkamp, Frans L. G., Sosef, Meindert N., Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989456/
https://www.ncbi.nlm.nih.gov/pubmed/27535748
http://dx.doi.org/10.1186/s12885-016-2709-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989456/
https://www.ncbi.nlm.nih.gov/pubmed/27535748
http://dx.doi.org/10.1186/s12885-016-2709-z

Ejemplares similares